Skip to content
stockhead logo
close
  • JUST IN
  • SECTIONS
    • Mining
    • Health & Biotech
    • Technology
    • Energy
    • Food & Agriculture
  • FEATURES
    • IPO Watch
    • Escrow Watch
    • Director Trades
    • Private-i
    • Aftermarket
    • The Secret Broker
  • PRIMERS
  • STOCKHEAD TV
  • SEARCH
  • SUBSCRIBE

Health & Biotech

Health Kick Podcast: Investing in repurposed drugs, combating intracranial pressure and why Invex caught NASA’s eye

December 4, 2019December 4, 2019 | Tim Boreham

Tim Boreham is one of Australia’s best-known small cap analysts and business journalists.

Health & Biotech

Tim Boreham: Visioneering is flexing its muscles as it vies for a share of the $US2bn kids contact lens market

December 1, 2019December 3, 2019 | Tim Boreham

Health & Biotech

Health Kick Podcast: What’s holding back better breast cancer detection? And how is Volpara’s tech changing the game?

November 27, 2019December 4, 2019 | Tim Boreham

Tim Boreham is one of Australia’s best-known small cap analysts and business journalists.

Health & Biotech

Tim Boreham: Can Phylogica finally make magic happen after nearly 15 years of trying?

November 24, 2019November 24, 2019 | Tim Boreham

Health & Biotech

Health Kick Podcast: Developing drugs, fighting fibrosis and squeezing squishometers

November 20, 2019November 20, 2019 | Tim Boreham

Tim Boreham is one of Australia’s best-known small cap analysts and business journalists.

Health & Biotech

Dr Boreham’s Crucible: Uscom gets an A+ for everything but its share price

November 17, 2019November 17, 2019 | Tim Boreham

Health & Biotech

Health Kick Podcast: How Aussie health stocks are performing internationally and Prescient’s cancer-blocking innovation

November 13, 2019November 13, 2019 | Tim Boreham

Tim Boreham is one of Australia’s best-known small cap analysts and business journalists.

Health & Biotech

Dr Boreham’s Crucible: Genetic Signatures lures the deep-pocketed backers in the battle of the bugs

November 10, 2019November 15, 2019 | Tim Boreham

Health & Biotech

Health Kick Podcast: The growth of musculoskeletal disorders, new markets created by ageing populations and OCC’s Avatar moment

November 6, 2019November 6, 2019 | Tim Boreham

Tim Boreham is one of Australia’s best-known small cap analysts and business journalists.

Health & Biotech

Dr Boreham’s Crucible: PainChek on a painless path to success; shares up over 1000 per cent

November 3, 2019November 3, 2019 | Tim Boreham

Health & Biotech

Health Kick Podcast: The future of X-ray, a new way to image the body and challenging clinical practice

October 30, 2019October 30, 2019 | Tim Boreham

Tim Boreham is one of Australia’s best-known small cap analysts and business journalists.

Health & Biotech

Dr Boreham’s Crucible: Elixinol says FDA hemp call an ‘inflexion point’ for industry

October 27, 2019October 27, 2019 | Tim Boreham

1 2 3 … 11 Next » Next »

Hear it first with our daily newsletter.

We don't spam. Learn more about our Privacy Policy

Morning UpdateLunch Update

We don't spam. Read our privacy policy

Hear it first with our daily newsletter.

We don't spam. Learn more about our Privacy Policy

Morning UpdateLunch Update

We don't spam. Read our privacy policy

Most Popular

  • 1
    The health sector has been the ASX’s top performer in 2019, but could a recession stop it in its tracks?
  • 2
    On the Radar: 5 small caps that brokers pick for growth in the months ahead
  • 3
    Cox’s Find continues to unveil its high-grade gold riches for Great Southern
  • 4
    Tim Treadgold: Lithium stocks close to the bottom, it’s time to revisit a sold-down sector
  • 5
    IPO Watch: shhhh… there’s a new kid in town from Israel

Editor's Picks

  • 1
    This is where Australia’s biggest money men are putting their cash
  • 2
    On the Radar: 5 small caps that brokers pick for growth in the months ahead
  • 3
    The health sector has been the ASX’s top performer in 2019, but could a recession stop it in its tracks?
  • 4
    Explorers Podcast: Batting off takeover attempts, Thunderbox tales and base metal pricing in 2020
  • 5
    Who’s close to uncovering the next Nova or Fosterville?
stockhead logo
ABOUT US MEET THE TEAM CONTACT US ADVERTISE
facebook icon twitter icon instagram icon linkedin icon email icon

Stockhead is providing factual information where there is a reasonable likelihood of doubt.
The information is not intended to imply any recommendation or opinion about a financial product.

Terms of use Privacy Policy Copyright 2019
Do NOT follow this link or you will be banned from the site!

Hear it first with our daily newsletter.

We don't spam. Learn more about our Privacy Policy

Morning UpdateLunch Update

We don't spam. Read our privacy policy